AACR
Researchers Look to Validate Promising Immunotherapy Response Biomarker in Early-Stage Breast Cancer
Premium
MHC-II expression could be useful for guiding neoadjuvant immunotherapy in HER2-negative breast cancers, according to findings in Clinical Cancer Research.
The SMMART tumor board program has begun enrolling patients with pancreatic cancer, ovarian cancer, prostate cancer, sarcoma, and AML.
Startup OncXerna Therapeutics Explores Tumor Microenvironment to Help Guide Cancer Treatment
Premium
The Boston-based firm recently shared data indicating its RNA-seq panel can help guide colorectal cancer treatment with its in-licensed investigational drugs.
The firm will commercialize its Primary Immune Response assay as a laboratory-developed test to help guide immunotherapy decisions in lung cancer patients.
Recent results from the firm's case-control study cohort showed overall sensitivity of about 50 percent but higher performance for a subset of high-mortality cancers.